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and the reduction of risk was not linear. Further analy-
sis indicated that even in overlap groups where patients
exhibited equivalent mean LDL levels on treatment,
pravastatin treatment was associated with less risk of
occurrence of coronary events than placebo treatment.
These results suggest that while LDL leveldoes serve as
a predictor of the risk of coronary events, other factors
exist that should be considered and investigated further.
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ABSTRACT _
The West of Scotland Coronary Prevention Study
(WOSCOPS), a placebo-controlled 5-year cohort study,
demonstrated that the use of pravastatin decreased low
density lipoprotein (LDL) levels and associated risk of
myocardial infarction. The rate of occurrence of coro-
nary events, however, was similar across the four lowest
quintiles of LDL reduction (23-41 % reductions in mean
LDL levels). The relationship between reduction of LDL
Introduction
Measuring low density lipoproteins to assess indi-
vidual risk profiles for cardiovascular disease has
become an increasing focus for medical interven-
tion. Years ago, as Iipidologists were first separat-
ing chylomicrons into very low density (VLDL),
low density (LDL), intermediate density (IDL), and
high density lipoproteins (HDL), the recommended
course for measurement of risk profile was natu-
rally broad, and measurement of LDL might not
have been foremost on the list. High density lipo-
protein, non-HDL cholesterol, and even triglycer-
ides would have been suggested as the group of
lipid profile measurements to ascertain risk.
In 1988, when the West of Scotland Coronary
Prevention Study (WOSCOPS) was initiated Ill,
the objective was to lower cholesterol in individuals
with elevated levels, thereby reducing atheroscle-
rotic lesions. Shortly afterwards, interventional car-
diologists demonstrated that lowering LDL levels in
individuals with narrowed coronary arteries and
high levels of cholesterol does little in the short
term to alleviate constricted arteries f21. However,
there was short-term benefit seen in the reduction of
coronary events. It was believed, therefore, that al-
though LDL may be the key to the problem, it is not
the only factor governing the pathogenesis of athero-
sclerosis and the likelihood of having a myocardial
infarction. Further investigation was required.
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West of Scotland Coronary Prevention
Study: A Summary
The WOSCOPS study randomized subjects to ei-
ther a cholesterol-lowering drug or placebo. There
was great potential in the study to examine lipids
and lipoproteins (particularly LDL), and to evalu-
ate the relationship between health benefits and
the extent of LDL lowering. The study began with
6595 men between the ages of 45 and 64 who had
experienced no previous coronary events but pos-
sessed cholesterol levels between 250 and 300 mg/
dL. All subjects were put on an initial diet for a
period of 4 or 8 weeks so that individuals with
diet-resistant LDL levels between 175 and 230 mg/
dL could be identified. Of the 6595 men, 3293 were
assigned to placebo treatment and 3302 were given
a fixed dose of 40 mg of pravastatin without titra-
tion. The two groups were matched for mean LDL
levels, history of hypertension, and cigarette smok-
ing. Over the 5-year period of study a 31 % reduc-
tion in all infarcts (fatal and nonfatal), a 32 % re-
duction in cardiovascular mortality, and a 22%
reduction in total mortality were seen for those on
pravastatin treatment (Table 1).
Low Density Lipoprotein and Risk ofCoronary Events
Although there is much data showing a relationship
between LDL, lipid-lowering therapy, and risk of
coronary heart disease (CHD) [2-5], there was a
need to assess the complexity of this relationship
and whether LDL reduction alone explained the
benefits obtained from pravastatin in the West of
120
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Table I Early benefit with pravastatin in the West of Scotland Coronary Prevention Study
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Coronary events over 5 years (% with event)
Fatal and nonfatal infarcts
Cardiovascular mortality
Total mortality
Placebo
(n = 3293)
--------------
9.5
2.9
5.4
Adapted from [! J.
Pravastatin (40 mg)
(n = 3302)
6.4
1.9
4.3
Event reduction
with pravastatin
(%)
31
32
22
Scotland study. Intention-to-treat analysis of pri-
mary endpoints has been previously reported [l ],
Further post hoc analyses drive the conclusions of
this presentation. However, although these analy-
ses are useful for generating hypotheses, it is clear
that further research is necessary.
To examine the relationship between LOL level
and the. benefits bestowed by pravastarin, an on-
treatment analysis of the WOSCOPS data was de-
veloped. As a baseline measure, two separate assess-
ments of lipoprotein profiles at fasting were made
prior to randomization. Lipids were then measured
at 6-month intervals throughout the study, provid-
ing nine measurements of LDL cholesterol for those
men who lasted the study duration. To ensure par-
simony in hypothesis testing, and to examine the
actual treatment benefit, subjects were excluded
from further analysis if they maintained less than
75% treatment compliance, discontinued treatment
prior to the first assessment at 6 months, reached a
primary endpoint of myocardial infarction or CHD
death within the first 6 months, or had no follow-
up lipid assessment measurements. This resulted in
2065 patients on pravastatin treatment and 2616
on placebo. The groups were matched for demo-
graphic and lipid profile characteristics.
A follow-up intention-to-treat analysis f6j in-
cluding all study subjects verified the data shown
here. This analysis included different patient selec-
tion criteria, different overlap regions, and quintiles
instead of deciles in the Framingham analysis, and
came to virtually identical conclusions.
To examine LDL levels and the rate of coronary
events, the pravastatin subjects were divided into
quintiles according to the experienced reduction in
LOL. The first quintile had the lowest LDL reduc-
tion; the fifth quintile had the highest LOL reduc-
tion. A Cox proportional hazard model was used to
identify independent risk factors such as HDL, age,
and hypertension, and to adjust for their effects.
Patients in quintile 5 experienced a 41 % mean
LDL reduction and a 4°1,) chance of a coronary
event over the course of the study. Quintiles 4, 3,
and 2 were indistinguishable from quintile 5 with
respect to coronary events over the study period.
However, quintile 1 achieved only 10% reduction
of LDL, indicating a poor response to treatment. It
is possible that compliance, beyond that measured,
may have been partly responsible for this poor re-
sponse. In this quintile, the associated rate of coro-
nary events over the study period was 7.3%. In this
case a statistically significant difference in risk was
seen, with a risk ratio of 2.2 compared to quintile 5
(see Fig. 1). Furthermore, this risk of a coronary
event seen in quinrile 1 was equivalent to that seen
in the placebo group. LOL reduction apparently
provides only some predictive capability of cardio-
vascular events. \'V'hen LDL was reduced as in quin-
tiles 2 to 4, patients received as much benefit with
respect to reduced coronary events as did those in
quintile 5 who experienced maximal LDL reduction.
Although LDL lowering is an important contrib-
utor to event reduction, after about 25% reduction,
little additional benefit was demonstrated in the
WOSCOPS clinical trial. A linear relationship was
expected, but was not found, between event reduc-
tion and LOL reduction. The relationship in epide-
miological terms was curvilinear: Individuals with a
total cholesterol of 300 mgldL received more bene-
fit from having their LDL reduced by 25% than in-
dividuals beginning with lower total cholesterol and
receiving the same 25% reduction. This is analo-
gous to the principle of diminishing returns. Rela-
tive to the cost for initial therapeutic benefit, with
increasing LDL lowering the cost increases with
proportionally less return, and although benefits
may still accrue, they are not quantifia ble by cur-
rently used risk assessment measurements. Once
the relationship between LDL reduction and reduc-
tion in risk was determined not to be linear, other
factors were sought to account for changes in risk.
We next compared coronary event rates for sub-
jects in the placebo-treated and the pravastatin-
treated groups with comparable LOL levels for the
study duration. Most individuals on placebo treat-
ment had LDL levels above 170 mgldL, while most
on pravastatin treatment had levels below 150 mgl
dL. However, an overlap between the two groups
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Figure I Coronary event risk ratio (± 95%
CI) associated with pravastatin-induced de-
creases in low density lipoprotein (LDL)
levels. divided into quintiles from lowest
(quint ile I) to highest (quint ile 5) LDL re-
duction . p-value = statistical significance
from a risk ratio of I. (Adapted from Shep-
herd et al. [I].)
existed (Ta ble 2). Four hundred and fort y-six indi-
vidua ls on placebo treatment (average LDL1 62
mg/dL) exhibited a coronary event rate of 5.6%
over the study period; 466 pravastatin-treated pa-
tients (average LDL 159 mg/dL) showed a signifi-
cantl y different corona ry event rate of 3.8 %. In
oth er wo rds, pravastatin treatment alone produced
a 47% lower rate of coronary events compared to
placebo trea tment in matched subjects with the same
level of LDL. Other pravasrat in-related factors than
simply lowering LDL levels must exist to acco unt
for th is difference.
Analysis of West of Scotland Data Using the
Framingham Regression Model
Post hoc anal ysis of thi s type is fraught with diffi-
cult ies and must be interpreted with caution, but
the trend s found in the WOS COPS data were con-
sistent. Greate r benefit was alw ays seen for those
who were randomi zed to pra vasrarin rather than
placebo treatment, despite similar LDL levels. We
compa red the rate of coronary events predicted by a
Framingham anal ysis of the WOS COPS data to that
actu ally observed in the trial [3-5]. The Framing-
ham study assessed ca rdiovascular risk in individ-
uals over several yea rs. Incorporating facto rs such
as hypertension and diabetes diagnoses; age, gen-
der, and smoking status; and levels of HDL and
total plasma cholesterol; WOSCOPS data was ap-
plied to the Fram ingham regression model. This
model predicted rates of coro na ry events over the
study per iod for the placebo and pravastatin
groups, which were then compared to that seen in
the Frami ngham study (see Fig. 2). Thi s ana lysis
has some limit ati ons (e.g., WOSCOP S did not ac-
cou nt for all factors conta ined in the Framingham
model , such as left ventricular hypertrophy). De-
spite these limitation s, there was litt le difference
between the coronary event rate in the WOS COPS
placebo-treated group and that pred icted for it us-
ing the Fram ingh am risk equation. Howe ver, the
pravasratin-treated group exhibited consistently
lower event rates than predicted by the Framing-
ham model. Whereas the Framingham equ at ion
predicted a 22 % reduction in coronar y events,
WOSCOPS dat a demon str ated a 46% redu ction .
Again, thi s suggests th at pra vastarin- related event
redu ction was greater than predicted from the
LDL reduction alone.
Table 2 On-treatment low density lipoprotein cholesterol (LDL-C) overlap analysis of data from the West of Scotland
Coronary Prevention Study
On -treatment LDL-C average level (mg/dl)
Patients with coronary events over 4.5 years
Adapted from [ I].
Placebo
___(n = o4046}
162
5.6%
Pravastatin (40 mg)
(n = 466)
159
3.8%
Event reduction
with pravastatin
47%
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Framingham Analysis of WOSCOPS Placebo Data
Framingham An alys is of WOSCOPS Placebo Data
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Figure 2 The 4.5-year ob-
served percentage of occur-
rence of allcardiac events in
the group receiving (top)
placebo and (bottom) prav-
astatin in the WOSCOPS
trial compared to the per-
centage of events that was
predicted from Framingham
analysis. Notice that (top)
the observed values overlap
the predicted values. and
(bottom) the observed val-
ues are consistently lower
than the predicted values.
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Conclusions
Low density lipoprotein lowering is important since
a lower LDL is a necessary goal in helping patients
reduce the risk of myocardial infarction. The ques-
tion raised by this study is whether there is a limit
to the benefits of lowering LDL. In WOSCOPS a
maximal benefit was attained within the range of
lipid profiles examined. How is this relevant to the
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average hypercholesterolemic individual receiving
treatment? If a 25% reduction of LOL level pro-
vides most of the benefit (although greater reduc-
tion is attainable), further benefit will be difficult
to determine and costly to assess.
The degree of risk reduction witnessed in the
WOSCOPS trial with pravastatin is greater than
expected based on LOL reduction alone. There are
many possible explanations, but we should recon-
sider 1.01. as the sole relevant factor. Medications
such as pravasrarin influence many factors, such
as thromboses, endothelial function, smooth mus-
cle cell function, and inflammation. The interaction
of pravastatin with LOL receptors has effects be-
yond the alteration of LOL levels. For example,
because TOL is more efficiently bound to the LOL
receptor, IDL levels are even more effectively low-
ered than 1.01.; TOL is included within the spectrum
of particles measured as LOL in clinical laboratories.
As a result, although pravastatin affects changes to
atherogenicity of the lipoprotein profile, there is
currently no way to distinguish the various individ-
ual changes. Also, plasma and whole blood viscos-
ity are greatly reduced during pravastatin treatment,
possibly improving coronary blood flow and endot-
helial function. This reduced viscosity may account
for up to 25% of the reduction of coronary events.
Measuring 1.01. as a surrogate of the degree of med-
ical benefit is necessary but not sufficient. Several
other factors may significantly affect cardiovascular
Shepherd and Park
disease, and more research is required to identify
the best predictors.
This article was prepared with the assistance of Bio'Med-
Com Consultants inc., Montreal, Canada.
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